Skip to Content
Last Updated: 07/21/14

Program for the Assessment of Clinical Cancer Tests (PACCT)

Overview

Many decisions relating to cancer patient management depend on information derived from clinical laboratory tests. Significant research and development are involved in producing a test that is reliable enough for routine clinical use. CDP launched the Program for the Assessment of Clinical Cancer Tests (PACCT) in 2000 to develop a process for moving advances in new technologies and new understanding of cancer biology more efficiently and effectively into clinical practice.

PACCT is not a grants program. It leverages many NCI-supported activities to accomplish goals identified by the PACCT Strategy Group. The Strategy Group is comprised of experts from government and the private sector. Areas of expertise include clinical oncology, cancer biology, pathology, diagnostics technology, assay development, clinical trials methodology, statistics, regulatory processes, and patient advocacy. Smaller Working Groups are formed to handle specific projects, and workshops are convened to study particular challenges. Membership in the group varies over time, and additional expertise is sought as needed. The group revisits its mission frequently and makes adjustments as appropriate. This flexibility allows the Program to keep abreast of ever-evolving clinical needs and redirect its efforts accordingly.

PACCT Strategy Group Members

Jeff Abrams, M.D.
Acting Director for Clinical Research
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Rockville, MD

Robert L. Becker, M.D., Ph.D.
Chief Medical Officer
Division of Immunology and Hematology
Office of In Vitro Device Evaluation and Safety
Food and Drug Administration
Rockville, MD

Michael J. Birrer, M.D., Ph.D.
Professor in Medicine
Harvard Medical School
Boston, MA

Barbara Conley, M.D.
Associate Director
Cancer Diagnosis Program, DCTD
National Cancer Institute
Rockville, MD

Janet Dancey, M.D.
Program Leader, High Impact Clinical Trials
Ontario Institute for Cancer Research
Toronto, Ontario
Canada

L. Austin Doyle, M.D.
Senior Investigator
Investigational Drug Branch, CTEP
National Cancer Institute
Rockville, MD

David A. Eberhard
Director, Pre-Clinical Genomic Pathology
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC

Stanley R. Hamilton, M.D.
Professor and Head
Division of Pathology and Laboratory Medicine
M.D. Anderson Cancer Center
Houston, TX

Daniel F. Hayes, M.D.
Clinical Director, Breast Oncology Program
University of Michigan
Ann Arbor, MI

J. Milburn Jessup, M.D.
Chief, Diagnostics Evaluation Branch, DCTD
National Cancer Institute
Rockville, MD

Michael LeBlanc, Ph.D.
SWOG Statistical Center
Fred Hutchinson Cancer Research Center
Seattle, WA

Irina Lubensky, M.D.
Chief, Pathology Investigation & Resources Branch, CDP, DCTD
National Cancer Institute
Rockville, MD

Lynn M. Matrisian, Ph.D.
Vice President, Scientific and Medical Affairs
Pancreatic Cancer Action Network
Manhattan Beach, CA

Pamela McAllister, Ph.D.
Colon Cancer Alliance
Colorectal Cancer Network
Madison, WI

Lisa McShane, Ph.D.
Mathematical Statistician
Biometric Research Branch, DCTD
National Cancer Institute
Bethesda, MD

Larry Norton, M.D.
Professor and Director Breast Medical Oncology
Evelyn H. Lauder Breast Cancer Center
Memorial Sloan-Kettering Cancer Center
New York, NY

Soon Myung Paik, M.D.
Director, Division of Pathology
NSABP Foundation
Pittsburgh, PA

Richard Schilsky, M.D.
Chief Medical Officer
American Society of Clinical Oncology
Alexandria, VA

Daniel C. Sullivan, M.D.
Professor, Department of Radiology
Duke University Comprehensive Cancer Center
Durham, NC

Katherine M. Tynan, Ph.D.
Industry Consultant
Tynan Consulting, LLC
Emeryville, CA

Frederic Waldman, M.D., Ph.D.
Quest Diagnostics, Inc
San Juan Capistrano, CA